Posted inCardiology news
Vagal Nerve Stimulation in HFrEF Was Safe but Did Not Improve the Primary Composite Outcome in the ANTHEM-HFrEF Trial
In ANTHEM-HFrEF, vagal nerve stimulation in symptomatic HFrEF was feasible and safe, but the underpowered trial did not meet its primary efficacy endpoint after premature sponsor-driven termination.



















